---
document_datetime: 2024-05-28 09:13:53
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nuceiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nuceiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.0635331
conversion_datetime: 2025-12-24 23:46:43.254463
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nuceiva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                              |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0037               | Renewal of the marketing authorisation. | 21/03/2024                          | 17/05/2024                                  | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy,the CHMP considered that the benefit-risk balance of Nuceiva in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0029             | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol                                                                                                                                                                                 | 14/12/2023   | 17/05/2024   | Annex II               |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| IAIN/0036/G         | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 08/11/2023   | 17/05/2024   | SmPC, Labelling and PL |                                   |
| IA/0035             | B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                    | 05/09/2023   | n/a          |                        |                                   |
| PSUSA/10796 /202301 | Periodic Safety Update EU Single assessment - botulinum toxin type A (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                            | 31/08/2023   | n/a          |                        | PRAC Recommendation - maintenance |
| IB/0032/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                       | 02/05/2023   | n/a          |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change process                                     |            |     | B.II.d.2.d - Change in the manufacturing   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------|
| IB/0033/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor an approved test procedure | 12/04/2023 | n/a | changes to                                 |
| IAIN/0031 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/02/2023 | n/a |                                            |

<div style=\"page-break-after: always\"></div>

| IA/0030             | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 06/02/2023   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| II/0027             | B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 15/12/2022   | n/a   |                                   |
| PSUSA/10796 /202201 | Periodic Safety Update EU Single assessment - botulinum toxin type A (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/09/2022   | n/a   | PRAC Recommendation - maintenance |
| II/0025/G           | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 07/07/2022   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                          |            |            |                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IB/0026             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                             | 01/07/2022 | n/a        |                 |                                   |
| IAIN/0028           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                       | 07/06/2022 | 20/03/2023 | Annex II and PL |                                   |
| PSUSA/10796 /202107 | Periodic Safety Update EU Single assessment - botulinum toxin type A (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                | 10/03/2022 | n/a        |                 | PRAC Recommendation - maintenance |
| IA/0023/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 14/02/2022 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.c - Change in and/or limits of an AS,   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |                        | specification parameter   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------|
| IB/0022/G | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved                                                                                                                                                                         | 14/02/2022 | 20/03/2023 | SmPC and Labelling     | stability protocol        |
| T/0020    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/12/2021 | 24/01/2022 | SmPC, Labelling and PL |                           |
| IA/0021/G | This was an application for a group of variations. B.II.e.3.c - Change in test procedure for the immediate packaging of the finished product - Deletion of a test procedure if an alternative test procedure is already authorised                                                                                                                                                                                                                                  | 11/01/2022 | n/a        |                        |                           |

<div style=\"page-break-after: always\"></div>

|                     | B.II.e.3.c - Change in test procedure for the immediate packaging of the finished product - Deletion of a test procedure if an alternative test procedure is already authorised                                                                     |            |            |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| IB/0018             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                       | 14/12/2021 | 20/03/2023 | SmPC                              |
| II/0017             | Submission of the final reports of the non- interventional immunogenicity analysis (RMP cat 3 study). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 11/11/2021 | n/a        |                                   |
| PSUSA/10796 /202101 | Periodic Safety Update EU Single assessment - botulinum toxin type A (for centrally authorised products only)                                                                                                                                       | 02/09/2021 | n/a        | PRAC Recommendation - maintenance |
| IB/0016             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                             | 09/06/2021 | n/a        |                                   |
| IA/0015             | B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                            | 23/04/2021 | n/a        |                                   |
| PSUSA/10796 /202007 | Periodic Safety Update EU Single assessment - botulinum toxin type A (for centrally authorised products only)                                                                                                                                       | 11/03/2021 | n/a        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0013   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                       | 22/02/2021   | n/a        |                        |                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------|
| X/0005    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/11/2020   | 14/01/2021 | SmPC, Labelling and PL |                       |
| IB/0012/G | This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification to the specification with its corresponding | 22/12/2020   | n/a        |                        | parameter test method |
| IA/0011/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                                                                                                              | 27/11/2020   | n/a        |                        |                       |

<div style=\"page-break-after: always\"></div>

| IB/0008             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                        | 09/09/2020   | n/a        |                 |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| PSUSA/10796 /202001 | Periodic Safety Update EU Single assessment - botulinum toxin type A (for centrally authorised products only)                                                                                                                                                                                                                                           | 03/09/2020   | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0009/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 06/08/2020   | 14/01/2021 | Annex II and PL |                                   |
| IB/0007             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                           | 20/07/2020   | 14/01/2021 | Annex II        |                                   |
| IB/0003             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                        | 18/12/2019   | n/a        |                 |                                   |
| IA/0004             | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                                             | 17/12/2019   | n/a        |                 |                                   |
| IA/0001/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                      | 17/12/2019   | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

| A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|